Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13R?2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors

Stock Information for Mustang Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.